Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 22;37(33):e255.
doi: 10.3346/jkms.2022.37.e255.

Incidence and Pattern of Aminotransferase Elevation During Anti-Hypertensive Therapy With Angiotensin-II Receptor Blockers

Won Joon Choi #  1 , Gi-Ae Kim #  2 , Jaewon Park  1 , Sangmi Jang  1 , Woo Jin Jung  1 , Jae-Jun Shim  2 , Yewan Park  2 , Gwang Hyeon Choi  1 , Jin-Wook Kim  1 , Sook-Hyang Jeong  1 , Eun Sun Jang  3
Affiliations

Incidence and Pattern of Aminotransferase Elevation During Anti-Hypertensive Therapy With Angiotensin-II Receptor Blockers

Won Joon Choi et al. J Korean Med Sci. .

Abstract

Background: Angiotensin type II receptor blockers (ARBs) are the most widely used anti-hypertensive drugs. This study aimed to elucidate the likelihood and pattern of ARB-induced liver injury in a hospital-based cohort.

Methods: Data of patients receiving fimasartan (n = 5,543), candesartan (n = 6,406), valsartan (n = 6,040), and losartan (n = 9,126) were retrieved from the clinical data warehouse of two tertiary hospitals. Patients with alanine aminotransferase (ALT) levels > 5 times the upper normal limit were assessed according to the Roussel Uclaf Causality Assessment Method (RUCAM).

Results: A total of 27,115 patients were enrolled, including 14,630 (54.0%) men, with a mean age of 64.6 years (standard deviation, 13.6). During 31,717 person-years of ARB therapy, serum ALT levels > 120 IU/L were found in 558 (2.1%) person-years, and levels > 200 IU/L were found in 155 (0.6%) person-years. The incidence of ALT elevation > 120 IU/L per 106 cumulative defined daily doses was 6.6, 3.6, 3.9, and 4.0 in the fimasartan, candesartan, valsartan, and losartan groups, respectively (P = 0.002). An ALT level > 200 IU/L with RUCAM score ≥ 6 was found in 20 patients, suggesting probable drug-induced liver injury for 11 (0.2%) patients receiving fimasartan, five (0.1%) receiving candesartan, four (0.1%) receiving valsartan, and none receiving losartan (P < 0.001).

Conclusion: Approximately 2% of patients receiving ARB therapy had significant ALT elevation (4.24/106 cumulative defined daily doses [cDDDs]), which was associated with probable ARB-related liver injury in 0.07% of patients (0.15/106 cDDDs). Elevation of ALT was more commonly associated with fimasartan than the other ARBs. Clinicians should be aware of the possibility of ARB-related ALT elevation in patients with unexplained chronic abnormal ALT.

Keywords: Alanine Transaminase; Angiotensin II Type 2 Receptor Blockers; Chemical and Drug Induced Liver Injury; Fimasartan; Liver Function Tests.

PubMed Disclaimer

Conflict of interest statement

The authors have no potential conflicts of interest to disclose.

Figures

Fig. 1
Fig. 1. Flowchart of patient selection.
ARB = angiotensin type II receptor blocker, ALT = alanine aminotransferase, UNL = upper normal limit (40 IU/L), RUCAM = Roussel Uclaf Causality Assessment Method.
See this image and copyright information in PMC

Comment in

References

    1. Sindone A, Erlich J, Lee C, Newman H, Suranyi M, Roger SD. Cardiovascular risk reduction in hypertension: angiotensin-converting enzyme inhibitors, angiotensin receptor blockers. Where are we up to? Intern Med J. 2016;46(3):364–372. - PubMed
    1. Reports and Data. Angiotensin II receptor blockers market analysis, by type (Azilsartan, Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan) by application (Hypertension, Cardiovascular risks) forecasts to 2028. [Updated 2021]. [Accessed April 8, 2022]. https://www.reportsanddata.com/report-detail/angiotensin-ii-receptor-blo... .
    1. The Korean Society of Hypertension - Hypertension Epidemiology Research Working Group. Korea hypertension fact sheet 2021. [Updated 2021]. [Accessed April 8, 2022]. https://www.koreanhypertension.org/reference/guide?mode=read&idno=4581 .
    1. Losartan. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda, MD, USA: National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. [Updated 2017]. [Accessed April 8, 2022]. https://www.ncbi.nlm.nih.gov/books/NBK547842 . - PubMed
    1. Valsartan. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda, MD, USA: National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. [Updated 2017]. [Accessed April 8, 2022]. https://www.ncbi.nlm.nih.gov/books/NBK547944 . - PubMed